The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Burch, R. M.
Right arrow Articles by Sullivan, J. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Burch, R. M.
Right arrow Articles by Sullivan, J. P.

The Journal of Immunology, Vol 150, Issue 8 3397-3403, Copyright © 1993 by American Association of Immunologists

ARTICLES

Mice treated with a leumedin or antibody to Mac-1 to inhibit leukocyte sequestration survive endotoxin challenge

RM Burch, L Noronha-Blob, JM Bator, VC Lowe and JP Sullivan
Scios-Nova, Freeport Centre, Baltimore, MD 21224.

Endotoxin challenge causes metabolic dysfunction mediated by TNF, and sequestration of leukocytes. NPC 15669, N-carboxy-L-leucine, N-[2,7- dimethylfluoren-9-yl)methyl] ester, inhibits leukocyte recruitment into inflammatory lesions in animals, and inhibits endotoxin-induced neutropenia and lymphopenia in mice. This study was carried out to determine whether the ability of NPC 15669 to inhibit leukocyte sequestration is sufficient to promote survival after endotoxin challenge. To inhibit leukocyte sequestration directly, mice were treated with anti-CD11a (LFA-1) or anti-CD11b (Mac-1) before endotoxin challenge. Anti-CD11b partly inhibited neutropenia and lymphopenia in response to challenge with LPS, but anti--CD11a had little effect on leukopenia. At doses of 100 and 1000 micrograms/kg, anti-CD11b increased survival to endotoxin challenge from 0 to 20 and 40%, respectively, whereas anti-CD11a was without effect. These observations, coupled with the finding that NPC 15669 does not inhibit endotoxin-induced TNF release suggest that inhibition of leukocyte sequestration can increase survival after endotoxin challenge, and that NPC 15669 or antibodies to Mac-1 may represent effective therapies for gram-negative sepsis and shock.


This article has been cited by other articles:


Home page
 J Biomol ScreenHome page
J. Y. Park, M. Amin Arnaout, and V. Gupta
A Simple, No-Wash Cell Adhesion-Based High-Throughput Assay for the Discovery of Small-Molecule Regulators of the Integrin CD11b/CD18
J Biomol Screen, April 1, 2007; 12(3): 406 - 417.
[Abstract] [PDF]

Home page
 Innate ImmunityHome page
J.-M. Cavaillon and D. Annane
Invited review: Compartmentalization of the inflammatory response in sepsis and SIRS
Innate Immunity, June 1, 2006; 12(3): 151 - 170.
[Abstract] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
V. S. Bansal, S. Vaidya, E. P. Somers, M. Kanuga, D. Shevell, R. Weikel, and P. A. Detmers
Small Molecule Antagonists of Complement Receptor Type 3 Block Adhesion and Adhesion-Dependent Oxidative Burst in Human Polymorphonuclear Leukocytes
J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1016 - 1024.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1993 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1993 by The American Association of Immunologists, Inc. All rights reserved.